Protalix Biotherapeutics Reports New Data on ELELYSO, Oral GCD Will Be Presented at European Working Group on Gaucher Disease

Protalix BioTherapeutics, Inc.

announced today that new clinical data on ELELYSO™ and oral glucocerebrosidase (GCD), or oral GCD (PRX-112), will be presented at the European Working Group on Gaucher Disease 2014 11^th Meeting being held June 25-28 in Haifa, Israel, at the Dan Carmel Hotel. Professor Ari Zimran, M.D., Director of the Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, Israel, is scheduled to deliver the following three oral presentations: "Taliglucerase alfa in adult patients with Gaucher disease who were previously treated with imiglucerase: 36-month safety and efficacy results" on Friday, June 27 at 11:45 AM IDT. "Taliglucerase alfa 36-month clinical safety and efficacy in treatment-naïve patients" on Friday, June 27 at 2:30 PM IDT. "Novel treatment for Gaucher disease - oral administration of plant cells expressing GCD: Phase 1 study results and Phase 2a program" on Friday, June 27 at 3:30 PM IDT. Additional information regarding the conference can be found at the official website for the meeting, http://ewggd2014-israel.com/.